Summary
Background Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) disproportionately affect females, suggesting modulation by sex hormones. We sought to investigate whether symptom severity is influenced by changes in sex hormones over the menstrual cycle, or by hormonal contraception.
Methods We carried out a retrospective analysis of menstrual and symptom data, prospectively collected via the Visible app from individuals with long COVID, ME/CFS, or both, who had regular menstrual cycles, between 7th September 2022 and 6th March 2024. Mixed-effects models were used to examine associations between symptom severity, menstrual cycle phase and contraception type.
Findings 948 users were included; 100% of users were female and 92.6% identified as women. The most tracked symptoms were fatigue (99·5% of users), brain fog (88·3%), headaches (85·1%) and muscle aches (78·6%). All menstrual cycle phases showed a modest, but significant, improvement compared to the menstrual phase, most markedly the early luteal (IRR = 0·963, 95% CI: 0·958–0·968), but also the follicular (IRR = 0·985, 95% CI: 0·981–0·990) and late luteal phases (IRR = 0·980, 95% CI: 0·974– 0·985). Crashes (sudden and severe worsening of symptoms following exertion) were significantly more frequent during menstruation than in other phases. Users of combined hormonal contraception (n=70) had a statistically significant reduction in overall symptom score (OR = 0·827, 95% CI: 0·690–0·992) and crash incidence (OR = 0·548, 95% CI: 0·350–0·856) compared to those not using contraception (n=786).
Interpretation Menstruation is associated with worsened symptoms in long COVID and ME/CFS. Users of combined hormonal contraception report a lower symptom burden than non-users, suggesting a modulatory role of ovarian hormones. These findings could empower menstruating people living with long COVID and ME/CFS to anticipate cyclical changes in symptoms and plan their activities accordingly, and could also inform their use of contraception.
Funding UK Medical Research Council, NIHR, Community Jameel, the Eric and Wendy Schmidt Fund for Strategic Innovation, Bill & Melinda Gates Foundation, Borne, Action Medical Research, and Genesis Research Trust.
Competing Interest Statement
During the course of the study HL was employed by, and RP was a paid contractor for Visible Health Inc., the company that owns and operates the Visible app. Some of the study participants had paid for access to certain Visible features, though not access to symptom tracking or menstrual cycle tracking functionality which is free for all Visible app users. This was a study across both the free and paid user base. All other authors declare no competing interests.
Funding Statement
This study was funded by the Medical Research Council (grant number MR/W00710X/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was obtained from the Research Governance and Integrity Team (study number 277771) at Imperial College London
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.